Nurix Therapeutics, Inc. announces Resignation of Clay B. Siegall as Class II Member of the Board and as Member of the Board’s Compensation Committee and Development Advisory Committee

On May 15, 2022, Clay B. Siegall, Ph.D., notified the board of directors of Nurix Therapeutics, Inc. of his resignation as a Class II member of the Board and as a member of the Board's Compensation Committee and Development Advisory Committee, effective immediately.